Today on Drug Discovery & Development
FDA accepts NDA for intranasal epinephrine from ARS Pharmaceuticals
ARS Pharmaceuticals announced today that the FDA accepted its new drug application (NDA) for neffy, its intranasal epinephrine. The offering covers the emergency treatment of severe type I allergic reactions in children and adults weighing 30 kg (66 pounds) or more. The company set an anticipated target action date of mid-2023 for its PDUFA (Prescription…
Pfizer seeks EUA for omicron booster for under-5 kids
Pfizer (NYSE: PFE) and its COVID-19 vaccine partner BioNTech (Nasdaq: BNTX) today announced they’ve submitted a EUA application with the FDA for an omicron COVID-19 booster for children under 5. The companies are seeking authorization for their omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6…Drug Discovery and Development See More >
The top drug discovery predictions of 2023
Technology enabling the discovery and development of new drugs is rapidly evolving. We asked representatives from KBI Biopharma, Phylloceuticals and Provectus Algae for their drug discovery predictions on the platforms and technologies that will have the biggest impact on drug discovery efforts in 2023. 1. 2023 could be ‘massive showcase’ for ML in pharma Drug…
Sponsored Content See More >
Using Real-World Data to Address COVID-19By Cheryl Reifsnyder, PhD As a leading provider of data and advanced analytics, Veradigm understands the critical role real-world data…
Discovering Antigen-specific Monoclonal Antibodies using Single B Cell ScreeningIntroduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the…
A new way to access scientific papers?Losing university access doesn’t mean losing access to articles anymore By DeepDyve Digital Library Team Many researchers are surprised to…
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
The top drug discovery predictions of 2023
Technology enabling the discovery and development of new drugs is rapidly evolving. We asked representatives from KBI Biopharma, Phylloceuticals and Provectus Algae for their drug discovery predictions on the platforms and technologies that will have the biggest impact on drug discovery efforts in 2023. 1. 2023 could be ‘massive showcase’ for ML in pharma Drug…
Infectious Disease See More >
Pfizer seeks EUA for omicron booster for under-5 kids
Pfizer (NYSE: PFE) and its COVID-19 vaccine partner BioNTech (Nasdaq: BNTX) today announced they’ve submitted a EUA application with the FDA for an omicron COVID-19 booster for children under 5. The companies are seeking authorization for their omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6…
Lyme disease vaccine from Valneva and Pfizer has promising antibody persistence data
Combatting the rise of antimicrobial resistance
Pfizer and BioNTech’s updated bivalent booster retains protection against new omicron sublineages
Pfizer and BioNTech launch Phase 1 study of next-gen BNT162b4 COVID-19 vaccine
Oncology See More >
GSK’s Jemperli fares well in interim analysis of endometrial cancer trial
GSK (LSE/NYSE:GSK) has shared positive headline results from a planned interim analysis of Part 1 of a Phase 3 study of adults with primary advanced or recurrent endometrial cancer. In the study, patients in the Jemperli (dostarlimab) arm also received chemotherapy (carboplatin-paclitaxel) followed by Jemperli alone. The study tested the treatment regimen against chemotherapy with…
BioNTech to partner with Polish STING agonist firm Ryvu Therapeutics
Why GSK is pulling multiple myeloma drug Blenrep from U.S. market
AstraZeneca wins positive CHMP opinion for Imfinzi for unresectable or metastatic biliary tract cancer
